Fortitude Family Office’s Supernus Pharmaceuticals SUPN Stock Holding History

Fortitude Family Office’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$947	Sell	22 -31	-58%	-$1.41K	﹤0.01%	2267
2026 Q2	$2.46K	Buy	53 +45	+563%	+$2.16K	﹤0.01%	1408
2026 Q1	$414	Buy	8 +6	+300%	+$306	﹤0.01%	1791
2025 Q4	$99	Sell	2 -1	-33%	-$49	﹤0.01%	1894
2025 Q3	$143	Hold	3	–	–	﹤0.01%	1939
2025 Q2	$95	Buy	+3	New	+$96	﹤0.01%	2004

Other funds holding SUPN

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $451M AUM 22.13% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.82B AUM 22.19% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $263M AUM 26.23% 1-Year Est. Return

JWS

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Fortitude Family Office's SUPN Position: Q3 2026 in Review

Fortitude Family Office reduced its Supernus Pharmaceuticals (SUPN) stake by 58% in Q3 2026, selling an estimated $1.41K and leaving 22 shares worth $947. The position accounts for ﹤0.01% of the portfolio, ranked #2267.

Fortitude Family Office first reported a position in SUPN in Q2 2025 and has held it in 6 quarters since. The position peaked at $2.46K in Q2 2026. 25 funds tracked by Wall St. Rank hold SUPN as of Q3 2026.

Fortitude Family Office held 22 shares of Supernus Pharmaceuticals worth $947 as of Q3 2026.
Fortitude Family Office sold 31 Supernus Pharmaceuticals shares in Q3 2026, an estimated $1.41K.
Supernus Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2267 holding.
Fortitude Family Office first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Fortitude Family Office's Supernus Pharmaceuticals position peaked at $2.46K in Q2 2026.
25 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.